Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06707753
PHASE1/PHASE2

Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD

Sponsor: Beijing Anlong Biopharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

This Phase I/IIa study is designed to evaluate the safety, tolerability, preliminary pharmacodynamics and pharmacokinetics in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will receive a single dose of AL-001 administered via suprachoroidal space injection.

Official title: An Open-label, Nonrandomized, Single-arm, Single Dose, Dose-escalation Phase I/IIa Study to Evaluate the Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Macular Degeneration (wAMD)

Key Details

Gender

All

Age Range

50 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

21

Start Date

2023-09-11

Completion Date

2025-08-31

Last Updated

2025-03-19

Healthy Volunteers

No

Interventions

DRUG

AL-001

Administered via suprachoroidal space injection.

Locations (1)

Chinese Academy of Medical Sciences & Peking Union Hospital

Beijing, China